"5 Years of progress in Oral Biopharmaceutics
- IMI OrBiTo project and global biopharmaceutics research"
AstraZeneca, Granta Park, Cambridge, UK
Monday 17 - Tuesday 18 September 2018
The APS is pleased to announce this exciting 2 day meeting to review the progress and advances made by the collaborative IMI OrBiTo project . The OrBiTo project started in October 2012 and following a twelve-month non-cost extension phase will finish in October 2018.
The Innovative Medicines Initiative (IMI) ORBITO project is a pre-competitive collaboration between pharma, academia and specialist technology companies which aims to enhance our understanding of how orally-administered drugs are absorbed from the gastrointestinal tract and apply this knowledge to develop new in vitro tests and in silico models that will better predict the performance of oral formulations in patients (www.orbitoproject.eu).
‘The IMI OrBiTo programme has provided an opportunity for over 150 scientists from academia, industry and specialist technology companies to collaborate and develop our understanding of how the gastrointestinal tract processes oral dosage forms. This meeting is an opportunity to hear the key outputs from the 5 year research programme and discuss how these can be progressed in a regulatory context. I’m also really looking forward to hearing the latest from Professor Gordon Amidon’s FDA funded biopharmaceutics research programme and how the recent EU based biopharmaceutics initiatives, PEARRL and UNGAP are progressing’.
(Mark McAllister, OrBiTo Deputy Scientific Coordinator)
This open meeting will highlight key advances made by the consortium team
- across the four technical work packages,
- progress with industrial implementation of tools
- the regulatory opportunities for improved guidance on the use of in vitro and in silico approaches for oral biopharmaceutics.
The Biopharmaceutics collaborative ecosystem has significantly changed during the period of the OrBiTo programme and we will include updates from groups such as the Pharma IQ working group on dissolution, PEARRL, UNGAP and the FDA US oral biopharmaceutics research programme led by Professor Gordon Amidon.
This meeting is aimed at industrial and academic scientists working in the areas of biopharmaceutics, formulation design, regulatory CMC and analytical development. Scientists who are new to the area will also find the meeting useful for gaining a broad understanding of the key scientific and technical issues relevant to oral biopharmaceutics.
Poster presentations are welcomed from all attendees.
The nearest train station to the venue is
A list of local hotels is given below. The first two are closest. The Holiday Inn is adjacent to the station.
You should book directly with the hotel. Accommodation is not included in the course fees.